Design and structural optimization of novel SOS1 inhibitors in KRAS-driven cancers
Bioorganic & Medicinal Chemistry Letters · 2025
DOI: 10.1016/j.bmcl.2025.130282 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic & Medicinal Chemistry Letters, 2025. Verfasst von Yating Chen und 12 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, School of Pharmaceutical Sciences, Guizho…. Hauptthemen laut MEDLINE: SOS1 Protein, Proto-Oncogene Proteins p21(ras), Drug Design, Antineoplastic Agents. Die Arbeit nennt 29 Literaturangaben. Gefördert von: Zhongshan Science and Technology Bureau, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, National Natural Science Foundation of China.
Abstract (Originalsprache)
The development of small molecular inhibitors to target the guanine nucleotide exchange factor SOS1 has been proved to be a hopeful strategy for the treatment of various KRAS-driven cancers. Constructing novel SOS1 inhibitors is urgently needed due to the increasing drug resistance arising from structural similarity of earlier analogs. Herein, we discovered a new SOS1 inhibitor with para-dimethylaminoazetidine quinazoline scaffold. The most potent compound 10i showed superior activity to the reported SOS1 inhibitor Hit 1 in both the KRASG12C::SOS1 PPI inhibition assay and 3D proliferation inhibitory assay, and compound 10i presented enhanced aqueous solubility under physiologically relevant pH 6.8. Moreover, compound 10i could downregulate the levels of phosphorylated ERK and AKT in the NCI-H358 cancer cell line. Overall, these studies showed that 10i was a promising drug candidate for the treatment of KRAS-driven cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, School of Pharmaceutical Sciences, Guizhou Medical University, Guiyang 550014, China.
- Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; Faculty of Science and Engineering, The University of Nottingham Ningbo China, Ningbo 315100, China.
- School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210000, China.
- Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; University of Chinese Academy of Sciences, Beijing 101408, China.
- Faculty of Science and Engineering, The University of Nottingham Ningbo China, Ningbo 315100, China.
- Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan 528400, China.
Förderung
- Zhongshan Science and Technology Bureau
- Shanghai Institute of Materia Medica, Chinese Academy of Sciences
- National Natural Science Foundation of China
- Chinese Academy of Sciences
Zitieren
APA
Chen, Y., Liu, Q., Meng, X., Cao, W., Duo, L., Song, X., Shen, X., Low, S. S., Ho, W. Y., Tang, B., Zhang, P., Xie, H., & Xia, G. (2025). Design and structural optimization of novel SOS1 inhibitors in KRAS-driven cancers. Bioorganic & Medicinal Chemistry Letters. https://doi.org/10.1016/j.bmcl.2025.130282
Vancouver
Chen Y, Liu Q, Meng X, Cao W, Duo L, Song X, et al. Design and structural optimization of novel SOS1 inhibitors in KRAS-driven cancers. Bioorganic & Medicinal Chemistry Letters. 2025. doi:10.1016/j.bmcl.2025.130282
BibTeX
@article{Chen2025,
author = {Chen, Yating and Liu, Qiupei and Meng, Xianghui and Cao, Wenxu and Duo, Lihui and Song, Xiaorong and Shen, Xiangchun and Low, Sze Shin and Ho, Wan Yong and Tang, Bencan and Zhang, Pengli and Xie, Hua and Xia, Guoqin},
title = {Design and structural optimization of novel SOS1 inhibitors in KRAS-driven cancers},
journal = {Bioorganic & Medicinal Chemistry Letters},
year = {2025},
doi = {10.1016/j.bmcl.2025.130282}
}
EUVIMED